Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 6/2017

01-06-2017 | Review

Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview

Authors: Wei Xiong Wen, Siang Yin Lee, Rafaella Siang, Rhun Yian Koh

Published in: Advances in Therapy | Issue 6/2017

Login to get access

Abstract

Fibrosis is a potentially debilitating disease with high morbidity rates. It is estimated that half of all deaths that occur in the USA are attributed to fibrotic disorders. Fibrotic disorders are characterized primarily by disruption in the extracellular matrix deposition and breakdown equilibrium, leading to the accumulation of excessive amounts of extracellular matrix. Given the potentially high prevalence of fibrosis and the paucity of agents currently available for the treatment of this disease, there is an urgent need for the identification of drugs that can be utilized to treat the disease. Pentoxifylline is a methylxanthine derivative that is currently approved for the treatment of vascular diseases, in particular, claudication. Pentoxifylline has three main properties: improving the rheological properties of blood, anti-inflammatory, and antioxidative. Recently, the effectiveness of pentoxifylline in the treatment of fibrosis via attenuating and reversing fibrotic lesions has been demonstrated in several clinical trials and animal studies. As a result of the limited availability of antifibrotic agents in the long-term treatment of fibrosis that can attenuate and even reverse fibrotic lesions effectively, it would be of particular importance to consider the potential clinical utility of pentoxifylline in the treatment of fibrosis. Thus, this paper discusses the evolving roles of pentoxifylline in the treatment of different types of fibrosis.
Literature
1.
2.
Zeisberg M, Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol. 2013;304(3):C216–25.PubMedCrossRef
3.
4.
Ciechomska M, van Laar J, O’Reilly S. Current frontiers in systemic sclerosis pathogenesis. Exp Dermatol. 2015;24(6):401–6.PubMedCrossRef
5.
6.
Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47(1):243–53.PubMedPubMedCentralCrossRef
7.
Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.PubMedCrossRef
8.
Vanhaelen Q, Mamoshina P, Aliper AM, et al. Design of efficient computational workflows for in silico drug repurposing. Drug Discov Today. 2016;22(2):210–22.PubMedCrossRef
9.
Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ. 1996;155(8):1053–9.PubMedPubMedCentral
10.
Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med. 1999;159(4):337–45.PubMedCrossRef
11.
Ogrin R, Duncan G, Warmington S, Darzins P. Is pentoxifylline an underused drug? Prim Intent. 2003;11(3):141–4.
12.
Perego MA, Sergio G, Artale F, Giunti P, Danese C. Haemorrheological improvement by pentoxifylline in patients with peripheral arterial occlusive disease. Curr Med Res Opin. 1986;10(2):135–8.PubMedCrossRef
13.
Soria J, Giovannangeli ML, Jolchine IE, Chassoux G. Pentoxifylline, fibrinogen and leukocytes. Blood Coagul Fibrinolysis. 1990;1(4–5):485–7.PubMedCrossRef
14.
Fossat C, Fabre D, Alimi Y, et al. Leukocyte activation study during occlusive arterial disease of the lower limb: effect of pentoxifylline infusion. J Cardiovasc Pharmacol. 1995;25(Suppl 2):S96–100.PubMedCrossRef
15.
Zargari O. Pentoxifylline: a drug with wide spectrum applications in dermatology. Dermatol Online J. 2008;14(11):2.PubMed
16.
Zhang M, Xu YJ, Mengi SA, Arneja AS, Dhalla NS. Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. Exp Clin Cardiol. 2004;9(2):103–11.PubMedPubMedCentral
17.
Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987;34(1):50–97.PubMedCrossRef
18.
Sloczynska K, Kozka M, Pekala E, Marchewka A, Marona H. In vitro effect of pentoxifylline and lisofylline on deformability and aggregation of red blood cells from healthy subjects and patients with chronic venous disease. Acta Biochim Pol. 2013;60(1):129–35.PubMed
19.
Tong Z, Dai H, Chen B, Abdoh Z, Guzman J, Costabel U. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest. 2003;124(4):1526–32.PubMedCrossRef
20.
Pollice PF, Rosier RN, Looney RJ, Puzas JE, Schwarz EM, O’Keefe RJ. Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes: a potential treatment for aseptic loosening of total joint components. J Bone Joint Surg Am. 2001;83(7):1057–61.PubMedCrossRef
21.
Ferrari P, Mallon D, Trinder D, Olynyk JK. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology. 2010;15(3):344–9.PubMedCrossRef
22.
Gonzalez-Espinoza L, Rojas-Campos E, Medina-Perez M, Pena-Quintero P, Gomez-Navarro B, Cueto-Manzano AM. Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial. Nephrol Dial Transplant. 2012;27(5):2023–8.PubMedCrossRef
23.
Gutierrez-Reyes G, Lopez-Ortal P, Sixtos S, et al. Effect of pentoxifylline on levels of pro-inflammatory cytokines during chronic hepatitis C. Scand J Immunol. 2006;63(6):461–7.PubMedCrossRef
24.
Crouch SP, Fletcher J. Effect of ingested pentoxifylline on neutrophil superoxide anion production. Infect Immun. 1992;60(11):4504–9.PubMedPubMedCentral
25.
Hinze HJ. Pharmacokinetics of 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine (BL 191) in man. Arzneimittelforschung. 1972;22(9):1492–5.PubMed
26.
Magnusson MV. Pharmacokinetics and pharmacodynamics of pentoxifylline and metabolites. Lund University, Faculty of Medicine, Doctoral Dissertation Series. 2009;29.
27.
Smith RV, Waller ES, Doluisio JT, et al. Pharmacokinetics of orally administered pentoxifylline in humans. J Pharm Sci. 1986;75(1):47–52.PubMedCrossRef
28.
Bryce TA, Burrows JL. Determination of oxpentifylline and a metabolite, 1-(5′-hydroxyhexyl)-3,7-dimethylxanthine, by gas–liquid chromatography using a nitrogen-selective detector. J Chromatogr. 1980;181(3–4):355–61.PubMedCrossRef
29.
Ings RM, Nudemberg F, Burrows JL, Bryce TA. The pharmacokinetics of oxpentifylline in man when administered by constant intravenous infusion. Eur J Clin Pharmacol. 1982;23(6):539–43.PubMedCrossRef
30.
Poirier JM, Lebot M, Cheymol G. In vitro demonstration of hydroxylation of pentoxifylline. Therapie. 1989;44(1):69–70.PubMed
31.
Lillibridge JA, Kalhorn TF, Slattery JT. Metabolism of lisofylline and pentoxifylline in human liver microsomes and cytosol. Drug Metab Dispos. 1996;24(11):1174–9.PubMed
32.
Nicklasson M, Bjorkman S, Roth B, Jonsson M, Hoglund P. Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. Chirality. 2002;14(8):643–52.PubMedCrossRef
33.
Sora DI, Cristea E, Albu F, David V, Medvedovici A. Bioanalysis of pentoxifylline and related metabolites in plasma samples through LC-MS/MS. Biomed Chromatogr. 2010;24(6):663–74.PubMed
34.
Rames A, Poirier JM, LeCoz F, et al. Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. Clin Pharmacol Ther. 1990;47(3):354–9.PubMedCrossRef
35.
Mauro VF, Mauro LS, Hageman JH. Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. J Clin Pharmacol. 1992;32(11):1054–8.PubMedCrossRef
36.
Hinze HJ, Bedessem G, Soder A. Structure of excretion products of 3,7-dimethyl-1-(5-oxo-hemyl)-xanthine (BL 191) in man. Arzneimittelforschung. 1972;22(7):1144–51.PubMed
37.
Lefaix JL, Delanian S, Vozenin MC, Leplat JJ, Tricaud Y, Martin M. Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and alpha-tocopherol: an experimental study. Int J Radiat Oncol Biol Phys. 1999;43(4):839–47.PubMedCrossRef
38.
Boerma M, Roberto KA, Hauer-Jensen M. Prevention and treatment of functional and structural radiation injury in the rat heart by pentoxifylline and alpha-tocopherol. Int J Radiat Oncol Biol Phys. 2008;72(1):170–7.PubMedPubMedCentralCrossRef
39.
Liu H, Xiong M, Xia YF, et al. Studies on pentoxifylline and tocopherol combination for radiation-induced heart disease in rats. Int J Radiat Oncol Biol Phys. 2009;73(5):1552–9.PubMedCrossRef
40.
Bese NS, Munzuroglu F, Uslu B, et al. Vitamin E protects against the development of radiation-induced pulmonary fibrosis in rats. Clin Oncol. 2007;19(4):260–4.CrossRef
41.
Kaya V, Yazkan R, Yildirim M, et al. The relation of radiation-induced pulmonary fibrosis with stress and the efficiency of antioxidant treatment: an experimental study. Med Sci Monit. 2014;20:290–6.PubMedPubMedCentralCrossRef
42.
Yamashita T, Boros DL. IL-4 influences IL-2 production and granulomatous inflammation in murine Schistosomiasis mansoni. J Immunol. 1992;149(11):3659–64.PubMed
43.
Reis LF, Ventura TG, Souza SO, et al. Quantitative and qualitative interferences of pentoxifillyne on hepatic Schistosoma mansoni granulomas: effects on extracellular matrix and eosinophil population. Mem Inst Oswaldo Cruz. 2001;96(Suppl):107–12.PubMedCrossRef
44.
Mati VL, Freitas RM, Melo AL. Effects of pentoxifylline during Schistosoma mansoni infection in Swiss mice: an analysis of worm burden, fecundity and liver histopathology. J Helminthol. 2010;84(4):348–54.PubMedCrossRef
45.
Xiong LJ, Zhu JF, Luo DD, Zen LL, Cai SQ. Effects of pentoxifylline on the hepatic content of TGF-beta1 and collagen in Schistosomiasis japonica mice with liver fibrosis. World J Gastroenterol. 2003;9(1):152–4.PubMedPubMedCentralCrossRef
46.
El-Lakkany N, Nosseir M. Pharmacodynamics of pentoxifylline and/or praziquantel in murine Schistosomiasis mansoni. APMIS. 2007;115(3):184–94.PubMedCrossRef
47.
El-Lakkany N, El-Din SS, Ebeid F. The use of pentoxifylline as adjuvant therapy with praziquantel downregulates profibrogenic cytokines, collagen deposition and oxidative stress in experimental Schistosomiasis mansoni. Exp Parasitol. 2011;129(2):152–7.PubMedCrossRef
48.
Naranjo TW, Lopera DE, Diaz-Granados LR, Duque JJ, Restrepo AM, Cano LE. Combined itraconazole-pentoxifylline treatment promptly reduces lung fibrosis induced by chronic pulmonary paracoccidioidomycosis in mice. Pulm Pharmacol Ther. 2011;24(1):81–91.PubMedCrossRef
49.
Lopera DE, Naranjo TW, Hidalgo JM, et al. Pentoxifylline immunomodulation in the treatment of experimental chronic pulmonary paracoccidioidomycosis. Fibrogenesis Tissue Repair. 2015;8:10.PubMedPubMedCentralCrossRef
50.
Fang CC, Lai MN, Chien CT, et al. Effects of pentoxifylline on peritoneal fibroblasts and silica-induced peritoneal fibrosis. Perit Dial Int. 2003;23(3):228–36.PubMed
51.
Hung KY, Huang JW, Chiang CK, Tsai TJ. Preservation of peritoneal morphology and function by pentoxifylline in a rat model of peritoneal dialysis: molecular studies. Nephrol Dial Transplant. 2008;23(12):3831–40.PubMedCrossRef
52.
Fang CC, Huang JW, Shyu RS, et al. Fibrin-Induced epithelial-to-mesenchymal transition of peritoneal mesothelial cells as a mechanism of peritoneal fibrosis: effects of pentoxifylline. PLoS One. 2012;7(9):e44765.PubMedPubMedCentralCrossRef
53.
Tarhan OR, Barut I, Sutcu R, Akdeniz Y, Akturk O. Pentoxifylline, a methyl xanthine derivative, reduces peritoneal adhesions and increases peritoneal fibrinolysis in rats. Tohoku J Exp Med. 2006;209(3):249–55.PubMedCrossRef
54.
D’Amico G, Ferrario F, Rastaldi MP. Tubulointerstitial damage in glomerular diseases: its role in the progression of renal damage. Am J Kidney Dis. 1995;26(1):124–32.PubMedCrossRef
55.
Lin SL, Chen RH, Chen YM, et al. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol. 2005;16(9):2702–13.PubMedCrossRef
56.
Zhou QG, Zheng FL, Hou FF. Inhibition of tubulointerstitial fibrosis by pentoxifylline is associated with improvement of vascular endothelial growth factor expression. Acta Pharmacol Sin. 2009;30(1):98–106.PubMedCrossRef
57.
Shirazi M, Noorafshan A, Farrokhi A. Effects of pentoxifylline on renal structure after urethral obstruction in rat: a stereological study. Cent Eur J Urol. 2011;64(1):30–3.CrossRef
58.
Zang Z, Li S, Lin Y, et al. Pentoxifylline prevents driamycin-induced myocardial fibrosis and apoptosis in rats. Int Heart J. 2015;56(6):651–5.PubMedCrossRef
59.
60.
Delanian S. Striking regression of radiation-induced fibrosis by a combination of pentoxifylline and tocopherol. Br J Radiol. 1998;71(848):892–4.PubMedCrossRef
61.
Delanian S, Balla-Mekias S, Lefaix JL. Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol. J Clin Oncol. 1999;17(10):3283–90.PubMedCrossRef
62.
Haddad P, Kalaghchi B, Amouzegar-Hashemi F. Pentoxifylline and vitamin E combination for superficial radiation-induced fibrosis: a phase II clinical trial. Radiother Oncol. 2005;77(3):324–6.PubMedCrossRef
63.
Okunieff P, Augustine E, Hicks JE, et al. Pentoxifylline in the treatment of radiation-induced fibrosis. J Clin Oncol. 2004;22(11):2207–13.PubMedCrossRef
64.
Delanian S, Porcher R, Balla-Mekias S, Lefaix JL. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol. 2003;21(13):2545–50.PubMedCrossRef
65.
Delanian S, Porcher R, Rudant J, Lefaix JL. Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. J Clin Oncol. 2005;23(34):8570–9.PubMedCrossRef
66.
Anscher MS. The irreversibility of radiation-induced fibrosis: fact or folklore? J Clin Oncol. 2005;23(34):8551–2.PubMedCrossRef
67.
Jacobson G, Bhatia S, Smith BJ, Button AM, Bodeker K, Buatti J. Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter. Int J Radiat Oncol Biol Phys. 2013;85(3):604–8.PubMedCrossRef
68.
Cook M, Johnson N, Zegzula HD, Schray M, Glissmeyer M, Sorenson L. Prophylactic use of pentoxifylline (Trental) and vitamin E to prevent capsular contracture after implant reconstruction in patients requiring adjuvant radiation. Am J Surg. 2016;211(5):854–9.PubMedCrossRef
69.
70.
Chiu CJ, Chang ML, Chiang CP, Hahn LJ, Hsieh LL, Chen CJ. Interaction of collagen-related genes and susceptibility to betel quid-induced oral submucous fibrosis. Cancer Epidemiol Biomark Prev. 2002;11(7):646–53.
71.
Murti PR, Bhonsle RB, Pindborg JJ, Daftary DK, Gupta PC, Mehta FS. Malignant transformation rate in oral submucous fibrosis over a 17-year-period. Community Dent Oral Epidemiol. 1985;13(6):340–1.PubMedCrossRef
72.
Rajendran R, Rani V, Shaikh S. Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis. Indian J Dent Res. 2006;17(4):190–8.PubMedCrossRef
73.
Mehrotra R, Singh HP, Gupta SC, Singh M, Jain S. Pentoxifylline therapy in the management of oral submucous fibrosis. Asian Pac J Cancer Prev. 2011;12(4):971–4.PubMed
74.
Patil S, Maheshwari S. Efficacy of pentoxifylline in the management of oral submucous fibrosis. J Orofac Sci. 2014;6(2):94–8.CrossRef
75.
Prabhu N, Rao SS, Kotrashetti SM, et al. Pentoxifylline in patients with oral submucous fibrosis-a randomized clinical trial. J Maxillofac Oral Surg. 2015;14(1):81–9.PubMedCrossRef
76.
Devi BC, Pisani P, Tang TS, Parkin DM. High incidence of nasopharyngeal carcinoma in native people of Sarawak, Borneo Island. Cancer Epidemiol Biomarkers Prev. 2004;13(3):482–6.PubMed
77.
Petta S, Valenti L, Bugianesi E, et al. A “systems medicine” approach to the study of non-alcoholic fatty liver disease. Dig Liver Dis. 2016;48(3):333–42.PubMedCrossRef
78.
79.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.PubMedCrossRef
80.
Italian Association for the Study of the Liver (AISF), Lonardo A, Nascimbeni F, et al. AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. Dig Liver Dis. 2017;. doi:10.​1016/​j.​dld.​2017.​01.​147.
81.
Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557–65.PubMedCrossRef
82.
Lonardo A, Sookoian S, Pirola CJ, Targher G. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism. 2016;65(8):1136–50.PubMedCrossRef
83.
Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600.PubMedCrossRef
84.
Sawangjit R, Chongmelaxme B, Phisalprapa P, et al. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): a PRISMA-compliant systematic review and network meta-analysis. Medicine. 2016;95(32):e4529.PubMedPubMedCentralCrossRef
85.
Singh S, Khera R, Allen AM, Murad MH, Loomba R. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis. Hepatology. 2015;62(5):1417–32.PubMedCrossRef
86.
Zeng T, Zhang CL, Zhao XL, Xie KQ. Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies. Eur J Gastroenterol Hepatol. 2014;26(6):646–53.PubMed
87.
Zein CO, Lopez R, Fu X, et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology. 2012;56(4):1291–9.PubMedPubMedCentralCrossRef
88.
Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie’s disease: results of a large survey. BJU Int. 2001;88(7):727–30.PubMedCrossRef
89.
Mulhall JP, Creech SD, Boorjian SA, et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171(6 Pt 1):2350–3.PubMedCrossRef
90.
Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of Peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol. 2011;2011:282503.PubMedPubMedCentralCrossRef
91.
Abern MR, Larsen S, Levine LA. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie’s disease. J Sex Med. 2012;9(1):288–95.PubMedCrossRef
92.
Brant WO, Dean RC, Lue TF. Treatment of Peyronie’s disease with oral pentoxifylline. Nat Clin Pract Urol. 2006;3(2):111–5.PubMedCrossRef
93.
Dell’Atti L, Ughi G. Efficacy of pentoxifylline in Peyronie’s disease: clinical case of a young man. Arch Ital Urol Androl. 2014;86(3):237–8.PubMedCrossRef
94.
Smith JF, Shindel AW, Huang YC, et al. Pentoxifylline treatment and penile calcifications in men with Peyronie’s disease. Asian J Androl. 2011;13(2):322–5.PubMedCrossRef
95.
Paulis G, Barletta D, Turchi P, et al. Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie’s disease: a case-control study. Res Rep Urol. 2016;8:1–10.PubMed
96.
Shindel AW, Lin G, Ning H, et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J Sex Med. 2010;7(6):2077–85.PubMedPubMedCentralCrossRef
97.
Lin G, Shindel AW, Banie L, et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1. J Sex Med. 2010;7(5):1787–97.PubMedPubMedCentralCrossRef
98.
Mitchell DN, Scadding JG. Sarcoidosis. Am Rev Respir Dis. 1974;110(6):774–802.PubMed
99.
Thomas PD, Hunninghake GW. Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis. 1987;135(3):747–60.PubMed
100.
Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 1989;56(5):731–40.PubMedCrossRef
101.
Schade UF. Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock. 1990;31(2):171–81.PubMed
102.
Zabel P, Wolter DT, Schonharting MM, Schade UF. Oxpentifylline in endotoxaemia. Lancet. 1989;2(8678–8679):1474–7.PubMedCrossRef
103.
Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 1997;155(5):1665–9.PubMedCrossRef
104.
Park MK, Fontana JR, Babaali H, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):121–31.PubMedPubMedCentral
105.
de Souza RB, Macedo AR, Kuruma KA, Macedo PA, Borges CT. Pentoxyphylline in association with vitamin E reduces cutaneous fibrosis in systemic sclerosis. Clin Rheumatol. 2009;28(10):1207–12.PubMedCrossRef
106.
Yasar S, Mumcuoglu CT, Serdar ZA, Gunes P. A case of lichen sclerosus et atrophicus accompanying bullous morphea. Ann Dermatol. 2011;23(Suppl 3):S354–9.PubMedPubMedCentralCrossRef
107.
Lee R, MacKinnon CA, Aburn N, Tan ST. Orbital immunoglobulin IgG4-related inflammatory fibrosclerosing lesion treated with pentoxifylline and alpha-tocopherol: case report. Br J Oral Maxillofac Surg. 2015;53(2):197–9.PubMedCrossRef
108.
Georges C, Lefaix JL, Delanian S. Case report: resolution of symptomatic epidural fibrosis following treatment with combined pentoxifylline-tocopherol. Br J Radiol. 2004;77(922):885–7.PubMedCrossRef
Metadata
Title
Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview
Authors
Wei Xiong Wen
Siang Yin Lee
Rafaella Siang
Rhun Yian Koh
Publication date
01-06-2017
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 6/2017
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-017-0547-2

Other articles of this Issue 6/2017

Advances in Therapy 6/2017 Go to the issue

Original Research

Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials

Erratum

Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA

Review

Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation

Original Research

Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers

Original Research

Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence

Original Research

Is There a Role for Ivabradine in the Contemporary Management of Patients with Chronic Heart Failure in Academic and Community Heart Failure Clinics in Canada?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits